Figure 1From: Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study Proportion of patients with a decrease in T2 lesion volume or T1 black hole (BH) volume from baseline to Year 3, by interferon (IFN) β-1a dose group. sc, subcutaneously; tiw, three times weekly.Back to article page